Biopharma

Biopharma Market Dynamics and Challenges

The current market conditions continue to exhibit an exciting rollercoaster from many biopharma companies. While FDA dynamics have been trending toward positive, there remains continuous pricing pressure from payers and patients. Despite what feels like an uncertain yet positive financing environment, early stage venture capital and later-stage private equity capital remain accessible for many companies as record amounts of funding continue to flow into the market in 2018.

Enter Locust Walk

For many emerging biopharma companies that need to raise capital via strategic partnerships or equity financings, we supplement a company’s C-suite or existing BD team with an expanded reach of capabilities, key contacts and long-standing relationships.

Locust Walk provides emerging biopharma companies with the strategic guidance and resources required to achieve their milestones and fulfill their potential. Since we don’t have the day-to-day pressures of managing a biopharma company, we can maintain a singular focus on helping to set strategy and then executing against the plan to deliver results for you regardless of the geographic focus of your deal.

Growth-oriented companies are often pursued as acquisition targets of other companies. Their best defense: Increasing scale and market valuation to stay beyond the reach of potential suitors and remain independent. For those that ultimately are acquired, on clinical and commercial capabilities and pipeline can often increase deal value. On the buy-side, most late-stage companies are looking to accelerate growth by bringing in additional clinical or commercial products.

Locust Walk is a market-maker with the ability to identify—uncovering overlooked assets—and transact target assets and companies across geographies, therapeutic areas, and modalities. Our comprehensive global footprint also enables the team to find assets wherever they reside. Strategic deals and transactions can help enable a company to go public, get to a commercial stage more quickly, fill a critical pipeline gap, or simply add another product to a sales rep’s “bag” to complement existing marketed products.

Locust Walk provides exciting new companies with the guidance and resources required to hit strategic growth benchmarks and fulfill their technological and market potential.

Our team’s deep industry experience enables us to help emerging biopharma firms scale up through rigorous assessment and analysis, connectivity with funding sources and strategic partners, and hands-on operational support.

Business & Corporate Development

Financing & IPO Advisory

OVERVIEW

Business case development

Targeted partner outreach

Due diligence staging

Deal structuring and evaluation

Contract negotiations

RESULTS

Data-driven approach

Structured process

Competitive tension and bidding

Real-time negotiations

Maximum deal value

OVERVIEW

Commercial assessment

Investor materials preparation

Targeted investor outreach

Due diligence staging

Deal comparables

Introductions to bankers and research analysts

S1 drafting (business section)

RESULTS

Robust understanding of opportunity

Succinct presentations

Relevant Investors

Competitive process

Realistic valuation and optimal outcome

Locust Walk offers a unique blend of exclusivity, superior deal flow, depth of expertise, and breadth of service for the growth biopharma sector.

Our international team of seasoned industry executives delivers specific, relevant operating deal experience. We provide comprehensive and exclusive guidance and support on both the buy-side and the sell-side.

Buy-side Process

Sell-side Process

OVERVIEW

Asset criteria development

Opportunity screening

Profile development

Target outreach

Due diligence

Deal structuring and evaluation

Contract negotiations

RESULTS

Strategic fit

Non-obvious opportunities

Timely decision-making

Transactability

Immediate increase in shareholder value

OVERVIEW

Business case development

Targeted partner outreach

Due diligence staging

Deal structuring and evaluation

Contract negotiations

RESULTS

Data-driven approach

Structured process

Competitive tension and bidding

Real-time negotiations

Maximum deal value

Locust Walk provides exciting new companies with the guidance and resources required to hit strategic growth benchmarks and fulfill their technological and market potential.

Our team’s deep industry experience enables us to help emerging biopharma firms scale up through rigorous assessment and analysis, connectivity with funding sources and strategic partners, and hands-on operational support.

Business & Corporate Development

OVERVIEW

Business case development

Targeted partner outreach

Due diligence staging

Deal structuring and evaluation

Contract negotiations

RESULTS

Data-driven approach

Structured process

Competitive tension and bidding

Real-time negotiations

Maximum deal value

Financing & IPO Advisory

OVERVIEW

Commercial assessment

Investor materials preparation

Targeted investor outreach

Due diligence staging

Deal comparables

Introductions to bankers and research analysts

S1 drafting (business section)

RESULTS

Robust understanding of opportunity

Succinct presentations

Relevant Investors

Competitive process

Realistic valuation and optimal outcome

Biopharma Transaction Highlights

CLIENT: Thar Pharmaceuticals

TRANSACTION:
Multi-Track Sell-Side and Financing Engagement Leading to Acquisition